Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001056827 | SCV001221291 | pathogenic | Osteogenesis imperfecta type I | 2019-06-20 | criteria provided, single submitter | clinical testing | This sequence change affects a donor splice site in the last intron (intron 50) of the COL1A1 gene. While this is not anticipated to result in nonsense mediated decay, it likely alters RNA splicing and results in a disrupted protein product. This variant is not present in population databases (ExAC no frequency). Disruption of this splice site has been observed in individuals affected with osteogenesis imperfecta type 3 or prenatal onset of multiple fractures (PMID: 25963598, Invitae), of whom it has been observed de novo in at least one individual (Invitae). Nucleotide substitutions within the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Experimental studies have shown that this variant disrupts mRNA splicing (PMID:25963598). For these reasons, this variant has been classified as Pathogenic. |